In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...

The FDA has approved a revised label for Merck’s immunotherapy drug Keytruda, limiting its use in some gastrointestinal cancer treatments to patients whose tumors express a minimum level of PD-L1 ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the ...